Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05346653 · ClinicalTrials.gov registry record · Phase 4
The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure
A Phase 4 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT05346653 is a Phase 4 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 1 participants.
The verdict
NCT05346653, a Phase 4 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
The main purpose of this study is to observe hemodynamic effects of initiating sodium-glucose co-transporter 2 inhibitors (SGLT2i) in patients admitted to the intensive care unit (ICU) with acute decompensated heart failure.
Interventions
- DRUG SGLT2i
- OTHER No SGLT2i
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-05-22 |
| Est. Completion | 2023-05-23 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05346653
The ClinicalTrials.gov registry entry for NCT05346653 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SGLT2i is the first listed.
NCT05346653 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05346653 about?
NCT05346653 is a clinical study titled "The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure". The main purpose of this study is to observe hemodynamic effects of initiating sodium-glucose co-transporter 2 inhibitors (SGLT2i) in patients admitted to the intensive care unit (ICU) with acute decompensated heart failure.
What is the current status of trial NCT05346653?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2023-05-22. Estimated completion is 2023-05-23.
What interventions are being tested in trial NCT05346653?
The interventions under investigation include: SGLT2i (DRUG), No SGLT2i (OTHER).
Who is sponsoring clinical trial NCT05346653?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.